Butterfly Network and Mendaera Unveil Next-Gen Interventional Robotic System with Ultrasound-on-Chip Technology

Agreement with Mendaera represents the first Powered by Butterfly™ commercialization partnership.

Butterfly Network, Inc., a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, and Mendaera, a Silicon Valley-based company developing technology to help healthcare providers more easily and confidently perform procedures through the power of medical robotics, announced an agreement to commercialize a novel robotic system that is Powered by Butterfly’s Ultrasound-on-Chip™ technology. Upon commercialization, the deal includes revenue share for every unit sold.

Mendaera’s robotic technology is compatible with Butterfly’s proprietary semiconductor-based ultrasound device and connected via Butterfly’s software development kit – Butterfly Garden™ – creating a system designed to improve precision and consistency for a broad range of image-guided, needle-based interventions. This new category of robotics will increase access to high quality interventional treatment, ultimately aiming to streamline patient care within a healthcare system burdened by workforce shortages and burnout. Both companies anticipate FDA submission of the product by 2025.

Recommended AI News: Riding on the Generative AI Hype, CDP Needs a New Definition in 2024

Recommended AI News: HGS Next-Gen Accelerator Harnesses Generative Artificial Intelligence for Contact Centers

“Mendaera’s robotic system is perfectly suited to leverage Butterfly’s proprietary Ultrasound-on-Chip™ by benefiting from the wide array of ultrasonic sensing applications that only our chip can offer,” said Darius Shahida, Chief Strategy Officer of Butterfly Network. “We are excited to welcome the Mendaera team as a Powered by Butterfly partner and believe our joint solution will expand Butterfly’s reach and clinical impact into the interventional space.”

“At Mendaera, we envision a world where high-quality intervention is available at every care facility, for each and every patient encounter. It was a clear choice for us to collaborate with Butterfly on our technology roadmap, given their unique and programmable Ultrasound-on-Chip™ platform and aligned mission to make ultrasonic imaging and intervention ubiquitous,” said Josh DeFonzo, Co-Founder and CEO of Mendaera.

Recommended AI News: ROC.ai Bolsters Leadership for Accelerated Growth in American-Made Biometrics

The news follows Mendaera’s August 2023 announcement of securing $24 million in Series A Funding, led by Lux Capital, with participation from Founders Fund, Operator Partners, Allen & Company, and Parade Ventures. Mendaera has also announced completion of the research and design process for this novel robotic system.

[To share your insights with us, please write to sghosh@martechseries.com]